According to a recent national survey, 17.1 percent of Americans lack health insurance, and more than nine million of the nation’s uninsured rely on federally qualified health centers (FQHC), non-profit community clinics and free clinics each year for primary care. While these clinics serve the critical health care needs of the uninsured, patients oftentimes cannot afford the medications prescribed by the clinic’s physicians, or navigate a fragmented system that only offers partial solutions. This is a particularly growing problem for America’s working poor.
Today, Medco Foundation and Dispensary of Hope (DOH), a not-for-profit pharmacy-focused social venture for the uninsured, introduced a new, national initiative to substantially improve the supply, delivery and management of critical prescription drugs to thousands of uninsured Americans who are managing a chronic illness.
To view Multimedia News Release, go to http://www.multivu.com/mnr/54424-medco-dispensary-of-hope-prescription-drug-program-clinics-uninsured
Sanofi (EURONEXT: SAN and NYSE: SNY) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that data from two Phase 2 trials with SAR236553/REGN727, an investigational, high-affinity, subcutaneously administered, fully-human antibody targeting PCSK9 (proprotein convertase subtilisin/kexin type 9), were presented at the American College of Cardiology’s (ACC) 61st Annual Scientific Meeting in Chicago.
The data showed that treatment with SAR236553/REGN727 over 8 to 12 weeks significantly reduced mean low-density lipoprotein-cholesterol (LDL-C, or “bad” cholesterol) by 40% to 72% in patients with elevated LDL-C on stable dose of statins.
To view Multimedia News Release, go to http://www.multivu.com/mnr/55299-sanofi-regeneron-pharmaceuticals-lipid-lowering-medications-pcsk9-antibody
A pill designed to zero in on abnormal genes that drive specific cancers has produced encouraging early results in children with an uncommon but aggressive type of lymphoma, as well as in children with a rare form of neuroblastoma.
A phase 1 clinical trial of the drug crizotinib achieved remissions, with minimal side effects, for 10 of the children participating in a clinical study carried out by the multicenter Children’s Oncology Group (COG). The results were “an exciting proof-of-principle” for the targeted treatment, said the study leader, Yaël P. Mossé, M.D., a pediatric oncologist at The Children’s Hospital of Philadelphia.
“We are entering a new era of cancer therapy, in which we use knowledge of basic biology to design very specific drugs that target cancer cells with potentially less side effects on healthy tissue,” said Mossé. “In addition, as we concentrate on targets in molecular pathways, we move away from an exclusive focus on one form of cancer to customizing treatments according to biological activity. Abnormal ALK activity occurs in subtypes of neuroblastoma and subtypes of lymphoma, so identifying ALK activity in individual patients may enable us to provide the most effective care.”
To view Multimedia News Release, go to http://www.multivu.com/mnr/50776-childrens-hospital-philadelphia-lymphoma-neuroblastoma-oncology-gene-trial
Raptor Pharmaceutical Corp. (“Raptor” or the “Company”) (Nasdaq: RPTP), today announced that the U.S. Food and Drug Administration (FDA) has approved PROCYSBI™ (cysteamine bitartrate) delayed release capsules for the treatment of nephropathic cystinosis in adults and children 6 years and older. In a Phase 3 study, PROCYSBI showed consistent cystine depletion over the full 12-hour dosing period. Sustained levels of cysteamine have not historically been achieved in the majority of patients in this population. Studies have shown that sustained cystine depletion in patients may significantly delay disease progression, including kidney dysfunction, dialysis, kidney transplant, organ failure and premature death.
To view Multimedia News Release, go to http://www.multivu.com/mnr/61338-raptor-pharmaceutical-procysbi-fda-approval-nephropathic-cystinosis
Janssen Healthcare Innovation, a team within Janssen Research & Development, LLC focusing on optimizing healthcare delivery, announced today the launch of Care4Today™ Mobile Health Manager 2.0 (mhm.care4today.com). This free mobile platform and website is designed to help people stay on schedule with their medications with special features such as Care4Family™ and Care4Charity™ to support and motivate users to take their medications regularly.
To view Multimedia News Release, go to http://www.multivu.com/mnr/62572-janssen-healthcare-innovation-launches-care4today-mobile-health-manager
CVS Health (NYSE:CVS), the nation’s largest pharmacy innovation company, today announced Be The First, a five-year $50 million initiative to help deliver the nation’s first tobacco-free generation. Through this initiative, which is funded through CVS Health and the CVS Health Foundation, the company is extending its commitment to help people lead tobacco-free lives. Recognizing that tobacco use is the leading preventable cause of disease and death in the United States and that youth use of some tobacco products is on the rise, Be The First comprises comprehensive education, advocacy, tobacco control and healthy behavior programming in partnership with organizations uniquely positioned to tackle this public health challenge.
“We are at a critical moment in our nation’s efforts to end the epidemic of tobacco use that continues to kill more people than any other preventable cause of death, and threatens the health and well-being of our next generation,” said Troyen A. Brennan, M.D., M.P.H., and Chief Medical Officer for CVS Health. “Ensuring our youth stay tobacco-free requires increased education and awareness of healthy behaviors. We’re partnering with experts across the public health community who have established best practices to help prevent tobacco use. And, by establishing more public-private partnerships to implement these strategies more aggressively, we can help increase the number of people leading tobacco-free lives and move us one step closer to delivering the first tobacco-free generation.”
To view the multimedia release go to:
http://www.multivu.com/players/English/7775151-cvs-health-be-the-first/
A new survey from the Gout & Uric Acid Education Society (GUAES) finds many Americans with gout may be placing too much emphasis on diet when it comes to managing the disease and controlling painful flares. Of all the steps taken to manage gout, respondents cited changing their diet by eliminating or reducing consumption of certain foods as their top step taken (50 percent)—even ahead of taking medications to lower their uric acid levels (40 percent) and maintaining an overall healthy fitness level (33 percent). Furthermore, nearly one in three with gout incorrectly believes that the disease can be completely avoided by eliminating certain foods; and more than one in four said they would not take medications if they were making dietary changes.
“Physicians all too often see patients who believe they can successfully manage their gout with diet alone,” said N. Lawrence Edwards, M.D., a rheumatologist and GUAES chairman. “But even with extremely rigid diet restrictions, most gout patients will only be able to lower their uric acid levels slightly—not nearly enough to achieve a healthy level to control flares and reduce risk for long-term damage.”
To view the multimedia release go to:
http://www.multivu.com/players/English/7835451-guaes-diet-survey/
The following statement is being issued by Branstetter, Stranch & Jennings, PLLC regarding In re Prograf Antitrust Litigation.
A lawsuit is currently pending claiming that Astellas Pharma US, Inc. (“Astellas” or “Defendant”) violated state antitrust, unfair competition, consumer protection, and unjust enrichment laws of certain states by delaying the availability of a less expensive generic version of the immunosuppressant prescription drug Prograf® (known as tacrolimus). Plaintiffs allege that Defendant’s conduct caused some consumers and third party payors to pay too much for Prograf in certain states from September 3, 2008 to December 31, 2010 (also referred to as the “Class Damage Period”). This lawsuit does not claim that Prograf is unsafe or ineffective. Astellas denies any wrongdoing.
To view the multimedia release go to:
http://www.multivu.com/players/English/7933851-prograf-antitrust-class-action-settlement/
Don’t trust us, trust Science: Abbott is among the best science-based companies to work for in the world.
For the 13th consecutive year, the journal Science today recognized Abbott on its Top Employers list, evaluated on 23 characteristics including financial strength, easy adaptation to change and a having a research-driven environment.
”Abbott is unique in that we’ve been adding to our reservoir of scientific knowledge for 128 years,“ said John Frels, Ph.D., chair of Abbott’s Scientific Governing Board, which oversees the company’s senior scientific career track. ”We strive to bring in the best and brightest scientists and engineers to work on some of the biggest problems in healthcare today. This helps us to create new, breakthrough innovations that change people’s lives.“
To view the multimedia release go to:
http://www.multivu.com/players/English/7962251-science-names-abbott-2016-top-employer/
http://tinnitusblog.org/low-blood-pressure-treatment-2/
Hypotension or low blood pressure is pressure that is lower than normal blood pressure. Regular blood vessels pressure for the human entire body is 120/80 mmHg. If your bp is 90/60 mmHg or reduce you may have reduced blood pressure.
Hypotension happens because of low blood flow through arteries and veins that can lead to less oxygen becoming passed to essential organs. This really is due to weakness, flabby and over dilated blood vessels. In situation of less oxygen becoming passed to brain, heart, eye and kidney, they are able to get harm and in some significant situations it can permanently damaged essential organs.
A few of the reasons that can cause hypotension are pregnancy, diabetes, the hormonal problems, hypothyroidism, hyperthyroidism, and low blood sugar. Some over-the-counter medications can also produce this issue. The overdose of higher bp drugs, abnormal center beats or rhythms, disrupting functioning of heart, heat stroke and liver illness might also trigger hypotension.
Some other factors that can cause sudden drops in blood vessels stress are loss of blood vessels, low body temperature, higher entire body temperature, sepsis, a severe blood infection, heart muscle disease causing heart failure, serious dehydration, due to reaction from medication and also the serious allergic response (anaphylaxis).
The main symptoms of low blood pressure are fainting, fatigue, dizziness, nausea, vertigo, transient blurring of vision, over exertion, mental disturbances, severe confusion and breathlessness. But with the normalization of the bp, these symptoms will subside gradually.
Drink lots of water as dehydration minimizes the blood volume which causes the drop in stress. Consume one glass of water per hour to keep your entire body hydrated. Salt can also be great for hypotension patient. You are able to improve your salt intake, but this improve in salt may vary from person to individual. Carry a walk after you take your meals. This assists in bringing the blood stress degree to regular.
Soak ten little raisins in water overnight. Chew every raisin gradually before swallowing it. Carry on doing this for a month. This really is very useful in normalizing reduced blood pressure. Another useful house remedy is almonds. Soak 5 almonds in drinking water overnight. Grind them to create a smooth paste and mix it in glass of milk. Boil the milk and drink it cozy.
Groundnuts have most of the needed nutrients and protein. Roasted groundnuts are more nourishing. Boil dates in sweetened milk. Take this milk warm along with the boiled dates, two or three times. Sugarcane juice is also a great energy booster and recommended for reduced bp.
Wheatgrass is believed to rejuvenate and revitalize the energy levels. Extract the juice and consume it immediately whilst nevertheless fresh for best result. Carry 2 to 4 grams of guggul twice a day together with hot milk, preferably within the winter months.
http://adultadhdtreatmentblog.com/adult-ritalin-is-this-effective-for-adult-adhd/ Occasionally trying to find an perfect grownup ADHD treatments and adult ritalin is really a seemingly endless array of medical medical doctors visits, medication modifications, and dosage adjustments. I understand your aggravation and share your discomfort. Nevertheless, existence will go on, so we must pick ourselves up and get back concerning the bus in make an effort to find that 1 grownup ADHD treatments that will assist us overcome those problematic grownup ADHD symptoms that may happen to be dogging us for years, for example inattention, impulsive behavior, and restlessness. Whilst this list won’t provide you with a brand new prescription drug alternative, it just might help you to improve your outcomes and minimize people pesky side effects. There